The “Cins” of Our Fathers: Rejuvenated Interest in Colicins to Combat Drug Resistance

Upatissa, Sumudu; Mitchell, Robert J.

doi:10.1007/s12275-023-00023-x

Cited by 3 publications

(4 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production of bacteriocins is a key mechanism that allows probiotic E. coli to compete with pathogenic microorganisms in the intestine by inhibiting their growth [ 25 ]. Numerous studies have shown that E. coli bacteriocins are effective against diarrheagenic E. coli [ 12 , 13 , 15 ] and related enteropathogenic bacteria such as Klebsiella , Salmonella , and Shigella [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies

Mihailovskaya,

Sutormin,

Karipova

et al. 2023

IJMS

View full text Add to dashboard Cite

Commensal bacteriocin-producing Escherichia coli are of interest for possible use as probiotics to selectively control the spread of pathogenic bacteria. Here, we evaluated the biosafety and efficacy of two new bacteriocin-producing E. coli strains, Q5 (VKM B-3706D) and C41 (VKM B-3707D), isolated from healthy farm animals. The genomes of both strains were sequenced, and genes responsible for the antagonistic and colonization abilities of each strain were identified. In vitro studies have shown that both strains were medium-adhesive and demonstrated antagonistic activity against most enteropathogens tested. Oral administration of 5 × 108 to 5 × 1010 colony-forming units of both strains to rats with drinking water did not cause any disease symptoms or side effects. Short-term (5 days) oral administration of both strains protected rats from colonization and pathogenic effects of a toxigenic beta-lactam-resistant strain of E. coli C55 and helped preserve intestinal homeostasis. Taken together, these in silico, in vitro, and in vivo data indicate that both strains (and especially E. coli Q5) can be potentially used for the prevention of colibacillosis in farm animals.

show abstract

Section: Discussionmentioning

confidence: 99%

Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies

Mihailovskaya,

Sutormin,

Karipova

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Similarly, a combinatorial approach like that described previously ( 19 ), where five colicins were used at once to prevent resistance development and increase efficacy, can be used alongside B. bacteriovorus to kill pathogenic E. coli strains that may be naturally resistant to a given colicin. Given plant-produced colicins recently received a favorable regulatory review as being generally regarded as safe (GRAS) ( 27 ) and are generally effective at controlling pathogens on foodstuffs ( 27 – 29 ), this represents one possible avenue for their coapplication alongside BALOs to reduce or prevent foodborne outbreaks. Other possibilities include their combined use to treat abiotic surfaces, such as stainless steel tabletops, where bacterial pathogens may be present and form biofilms ( 30 ).…”

Section: Observationmentioning

confidence: 99%

Pairing Colicins B and E5 with Bdellovibrio bacteriovorus To Eradicate Carbapenem- and Colistin-Resistant Strains of Escherichia coli

2023

Self Cite

View full text Add to dashboard Cite

The coupled impact of drug resistance with reduced antibiotic development has placed humankind at a postantibiotic crossroads where antibiotic alternatives are desperately needed. Consequently, we discuss here the combined effectiveness of two vastly different classes of antibacterials, namely, colicins and a predatory bacterium (i.e., Bdellovibrio bacteriovorus HD100), against two priority pathogenic groups, colistin- and carbapenem-resistant strains of E. coli

show abstract

“…In addition to SCFAs and D-amino acids, small proteins such as bacteriocins/colicins produced by gut Enterobacteriaceae have been shown to competitively inhibit the growth of pathogenic Salmonella enterica [ 86 ]. One of the very recent reviews by Upatissa and Mitchell [ 87 ] indicated the utilization of these small proteins to control specific drug-resistant pathogens. For example, microcin J25 has been shown to inhibit more than 28 multi-antibiotic-resistant Salmonella enterica serovars [ 88 ].…”

Section: Nutritional Interventionsmentioning

confidence: 99%

“…The protein also has shown effectiveness against some strains of multi-drug-resistant E. coli [ 89 ]. The work of Upatissa and Mitchell [ 87 ] provides a good insight into these proteins and their action mechanisms. In the case of cryptosporidiosis, cathelicidin-related anti-microbial peptides (CRAMPs) have been indicated to significantly reduce the parasite burden.…”

Section: Nutritional Interventionsmentioning

confidence: 99%

Intelligent Biological Networks: Improving Anti-Microbial Resistance Resilience through Nutritional Interventions to Understand Protozoal Gut Infections

2023

View full text Add to dashboard Cite

Enteric protozoan pathogenic infections significantly contribute to the global burden of gastrointestinal illnesses. Their occurrence is considerable within remote and indigenous communities and regions due to reduced access to clean water and adequate sanitation. The robustness of these pathogens leads to a requirement of harsh treatment methods, such as medicinal drugs or antibiotics. However, in addition to protozoal infection itself, these treatments impact the gut microbiome and create dysbiosis. This often leads to opportunistic pathogen invasion, anti-microbial resistance, or functional gastrointestinal disorders, such as irritable bowel syndrome. Moreover, these impacts do not remain confined to the gut and are reflected across the gut–brain, gut–liver, and gut–lung axes, among others. Therefore, apart from medicinal treatment, nutritional supplementation is also a key aspect of providing recovery from this dysbiosis. Future proteins, prebiotics, probiotics, synbiotics, and food formulations offer a good solution to remedy this dysbiosis. Furthermore, nutritional supplementation also helps to build resilience against opportunistic pathogens and potential future infections and disorders that may arise due to the dysbiosis. Systems biology techniques have shown to be highly effective tools to understand the biochemistry of these processes. Systems biology techniques characterize the fundamental host–pathogen interaction biochemical pathways at various infection and recovery stages. This same mechanism also allows the impact of the abovementioned treatment methods of gut microbiome remediation to be tracked. This manuscript discusses system biology approaches, analytical techniques, and interaction and association networks, to understand (1) infection mechanisms and current global status; (2) cross-organ impacts of dysbiosis, particularly within the gut–liver and gut–lung axes; and (3) nutritional interventions. This study highlights the impact of anti-microbial resistance and multi-drug resistance from the perspective of protozoal infections. It also highlights the role of nutritional interventions to add resilience against the chronic problems caused by these phenomena.

show abstract

The “Cins” of Our Fathers: Rejuvenated Interest in Colicins to Combat Drug Resistance

Cited by 3 publications

References 161 publications

Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies

Bacteriocin-Producing Escherichia coli Q5 and C41 with Potential Probiotic Properties: In Silico, In Vitro, and In Vivo Studies

Pairing Colicins B and E5 with Bdellovibrio bacteriovorus To Eradicate Carbapenem- and Colistin-Resistant Strains of Escherichia coli

Intelligent Biological Networks: Improving Anti-Microbial Resistance Resilience through Nutritional Interventions to Understand Protozoal Gut Infections

Contact Info

Product

Resources

About